Endocrine Testing Market Size, Share, Growth Opportunity Analysis Report by Test Type (Thyroid Function Tests (T3, T4, TSH), Adrenal Function Tests (Cortisol, ACTH), Reproductive Hormone Tests (Estrogen, Progesterone, Testosterone, LH, FSH), Glucose-related Tests (Insulin, C-peptide), Calcium & Parathyroid Tests (PTH, Calcium levels) and Others), Technology Platform, Sample Type, Mode of Testing, Pricing Tier, Indication/ Application, End-User Setting and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) – Global Industry Data, Trends, and Forecasts, 2025–2035
|
|
|
Segmental Data Insights |
|
|
Demand Trends |
|
|
Competitive Landscape |
|
|
Strategic Development |
|
|
Future Outlook & Opportunities |
|
Endocrine Testing Market Size, Share, and Growth
The growth of global endocrine testing market is likely to create a significant opportunity of USD 10.8 Billion during the forecasting period, 2025-2035. Increasing frequency of endocrine disorders and technological advances in diagnostics are the prime movers behind intruding demand for the global endocrine testing market. With thyroid, diabetes, and adrenal gland disorders on the rise, so does the increased requirement for frequent endocrine assessments. Having understood the need for better monitoring of diseases through faster and more accurate thyroid testing, Roche Diagnostics launched its second-generation Elecsys TSH assay in 2024.
"In February 2025, DiaSorin expanded its LIAISON XL platform with a new panel for thyroid and fertility hormone testing, targeting broader hospital and lab adoption across Europe and Asia. This strategic move aligns with CEO Carlo Rosa’s focus on strengthening DiaSorin’s specialty testing portfolio through innovation and global market penetration. The expansion enhances DiaSorin’s competitive position in endocrine diagnostics by offering high-throughput, automated testing tailored to evolving clinical demands."
The integration of automation into testing platforms will assist faster adoption in hospitals and labs, and thus Abbott launched its Alinity m platform in 2023 with a more complete hormone assay panel to support laboratory workflow and save on turnaround time. With facilitating these factors, the global reach of endocrine testing solutions and their clinical application is further enhanced, opening avenues to market growth.
Conversely, personalization of hormone replacement therapies (HRT), wearable biosensors for real-time hormone monitoring, and AI-empowered predictive diagnostics for endocrine disorders stand as some other major opportunities in the global endocrine testing market; these newcomer repositories too well complement the burgeoning push toward precision medicine and proactive health management. Adjacent innovations, thus, accentuate the value proposal of endocrine testing from a clinical as well as commercial perspective.
Endocrine Testing Market Dynamics and Trends
Driver: Rising Global Burden of Diabetes and Hormonal Disorders
- The endocrine testing market can be thought to be led by increasing cases of diabetes and disorders of hormonal imbalance like PCOS, adrenal insufficiency, and growth hormone disorders. As said by the International Diabetes Federation, in 2023, there are 537 million adults worldwide suffering from diabetes, with projections stating that this will go up to 643 million by 2030. The rise in these cases has, in turn, generated an increased demand for immediate endocrine testing with respect to adjuvant treatment and monitoring of the disease, mostly witnessed in developing countries seeing quick urbanization and sedentary lifestyles. Moreover, hormonal imbalance caused by environmental stressors or a bad diet and a changed lifestyle ensures regular endocrine panel reviews.
- In response to the market demand, Siemens Healthineers commissioned its ADVIA Centaur XPT Immunoassay System, designed for high throughput and automation operations relevant to high-volume endocrine biomarker testing such as insulin, cortisol, and estradiol. Since its exciting end to 2023, it has found considerable favor with clinical laboratories for its ability to deliver quick and accurate results, minimizing bottlenecks in operations.
- The rising global burden of endocrine disorders is directly boosting the demand for advanced testing platforms, accelerating market expansion.
Restraint: High Cost of Advanced Testing Equipment and Assays
- Principally in the developing countries, the high cost of instruments and reagents for endocrine testing remains the key restraint despite the increasing demand. Most advanced systems need heavy capital investment to be acquired, maintained, and trained for. Besides this, several hormone assays require rather special reagents that hike the per-test cost so much that smaller diagnostic centers cannot afford to either incorporate or upgrade their testing infrastructure. This cost challenge restricts the penetration of the market and blocks immediate diagnosis to resource-poor regions.
- For instance, in 2024, Beckman Coulter had launched its DxI 9000 Access Immunoassay Analyzer with higher sensitivity and extended test menus for endocrine diagnostics. Nevertheless, this initial investment and reagent pricing are affordably priced only for the Tier-1 centers, creating cost challenges for the Tier-2 and Tier-3 healthcare providers in Southeast Asia and Sub-Saharan Africa, wherein the system is getting adopted amongst more advanced economies. The limited reimbursement policy in developing nations creates another layer fortifying the cost barrier.
- Elevated costs of equipment and testing limit widespread adoption, especially in cost-sensitive markets, slowing overall market penetration.
Opportunity: Integration of Endocrine Testing in Point-of-Care (POC) Platforms
- The assessment is performed faster at the POC than in a centralized diagnostic laboratory. This decentralization, therefore, creates opportunities for endocrine testing at the point of care. In a scenario of chronic diseases such as hypothyroidism, diabetes, and testosterone deficiency, monitoring is often necessary, and faster testing through POC platforms will ensure easy availability from outpatient settings of general physicians, pharmacies, and even primary health centers. The paradigm shift towards patient-centric healthcare will promote the inclusion of telemedicine platforms with POC compact endocrine testing devices.
- BioMérieux has launched the miniaturized VIDAS 3 immunoassay system in 2024, which is tailored to the point of care, including small labs and patient outpatient clinics. This design permits semi-automated hormone testing of TSH, progesterone, and cortisol with minimum sample preparation, while the execution is with real-time results provision. Pilot testing undertaken on a global scale with clinics in France and Canada has highlighted that the system can be promising in early detection and treatment decisions in remote or underserved areas.
- Recognition towards secondary POC diagnostic testing opens new marketing opportunities and use cases for endocrine testing.
Key Trend: Adoption of Multiplex and AI-Driven Diagnostic Panels
- Another factor affecting the endocrine testing market is the acceptance of multiplex testing methods and AI-based analytics. They are used to detect numerous hormone levels all at once from one sample, thus facilitating and hastening diagnoses with efficiency and accuracy while cutting costs. In a manner, AI is becoming a major force to be reckoned with in reading intricate endocrine profiles, predicting disease course, and eventually carving out pathways for personalized treatment. These technologies have completely changed the perspective of endocrine diagnostics, leading to clinical decisions that are both intelligent and fast.
- One collaboration of this system ocurred in the beginning of 2025, when Thermo Fisher Scientific partnered with Tempus AI to combine Tempus's cloud-based, AI-powered platform consisting of real-time interpretation of endocrine profiles with Thermo Fisher's endocrine multiplex testing kits for metabolism and reproduction disorders. This system was initially installed in a few U.S. hospitals that reported 25% reduction in diagnosis time and increased physician confidence in therapy selection, which helped create more interest in endocrinologists and healthcare systems.
- The integration of multiplex and AI technologies is transforming endocrine diagnostics into a data-rich, predictive, and precision-driven healthcare solution.
Endocrine Testing Market Analysis and Segmental Data
Based on Test Type, the Thyroid Function Tests (T3, T4, TSH) Segment Retains the Largest Share
- The thyroid function tests (T3, T4, TSH) segment holds major share ~32% in the global endocrine testing market, due to the widespread prevalence of thyroid disorders such as hypothyroidism, hyperthyroidism, and autoimmune thyroiditis. Thyroid problems affect a big number of people, whereas many remain undiagnosed. Based on the American Thyroid Association, in the USA, it afflicts more than 20 million individuals. These tests are used for initial diagnosis and subsequent monitoring. Further promotion of the awareness and availability of regular screening programs worldwide is especially considering women and aged populations.
- In 2024, Roche Diagnostics extended the Elecsys TSH, FT3, and FT4 assay sand testing services for screening and treatment through ties with public health programs in emerging markets of the Asia-Pacific and Latin American regions. These automated immunoassays also extend the decision-making capability of clinicians in primary care settings with high precision and short turnaround times, which further contributed to the wide adoption.
- Considering an increasing number of cases of thyroid disorders and establishing new testing platforms, thyroid function tests continue to dominate the endocrine diagnostic segment.
North America Dominates Global Endocrine Testing Market in 2025 and Beyond
- North America demands endocrine tests mostly because of its high burden of diseases, advanced health infrastructure, and early adoption of newest technologies. Chronic endocrine disorders such as diabetes, disorders relating to obesity, and thyroid disorders are so common that they have been continuously screened and monitored. Further awareness among patients coupled with massive insurance supports make for frequent testing both in private practice and outpatient settings.
- During 2024, Labcorp stepped into providing expanded specialized endocrine diagnostic services across the United States by integrating Salivary Hormone Panels within the suite of routine checkups, particularly for women’s health and adrenal function monitoring. This novel approach serves the ever-growing need for non-invasive and highly tailored endocrine diagnostics, furthering North America's stronghold.
- Advanced health systems and a high level of disease awareness make North America the chief purchaser of endocrine testing solutions.
Endocrine Testing Market Ecosystem
Key players in the global endocrine testing market include prominent companies such as Abbott Laboratories, Roche Diagnostics, Siemens Healthineers, Beckman Coulter (Danaher), Bio-Rad Laboratories and Other Key Players.
The endocrine testing market is moderately fragmented, with the Tier 1 players like Abbott Laboratories, Roche Diagnostics, and Siemens Healthineers holding dominating positions, owing to their wide array of diagnostic portfolios and global distribution channels. Tier 2 and 3 players such as EUROIMMUN and IDS are involved in the niche business of hormone assays. Buyer concentration is moderate, governed by diagnostic labs and hospitals coming in the centralized form. On the other side, supplier concentration is high owing to a limited number of suppliers at the global scale, providing advanced reagents, antibodies, and analyzers.
Recent Development and Strategic Overview:
- In April 2025, with more AI integration, Quest Diagnostics introduced a thyroid panel with better diagnostic accuracy for TSH, T3, and T4, allowing for faster and more accurate recognition of subclinical thyroid disorders by clinicians.
- In March 2025, having received clearance from the US FDA, Roche Diagnostics' assay for Elecsys cortisol has facilitated analytical accuracy for adrenal disorder screening with faster turnaround time, useful in both hospital and high-throughput lab environments.
Report Scope
|
Detail |
|
|
Market Size in 2025 |
USD 11.5 Bn |
|
Market Forecast Value in 2035 |
USD 22.3 Bn |
|
Growth Rate (CAGR) |
6.2% |
|
Forecast Period |
2025 – 2035 |
|
Historical Data Available for |
2021 – 2024 |
|
Market Size Units |
US$ Billion for Value |
|
Report Format |
Electronic (PDF) + Excel |
|
North America |
Europe |
Asia Pacific |
Middle East |
Africa |
South America |
|
|
|
|
|
|
|
Companies Covered |
|||||
|
|
|
|
|
|
Endocrine Testing Market Segmentation and Highlights
|
Segment |
Sub-segment |
|
By Test Type |
|
|
By Technology Platform |
|
|
By Sample Type |
|
|
By Mode of Testing |
|
|
By Pricing Tier |
|
|
By Indication/ Application |
|
|
By End-User Setting |
|
Frequently Asked Questions
The global endocrine testing market was valued at 11.5 Bn in 2025.
The global endocrine testing market industry is expected to grow at a CAGR of 6.2% from 2025 to 2035.
The key factors driving demand for the endocrine testing market include the rising global prevalence of hormonal disorders such as diabetes, thyroid dysfunction, and reproductive health issues, along with increasing awareness and early screening initiatives. Moreover, advancements in automated immunoassay technologies, growing adoption of personalized medicine, and the expansion of diagnostic infrastructure especially in emerging markets are further accelerating market growth.
Thyroid Function Tests (T3, T4, TSH) contributed to the largest share of the endocrine testing market business in 2025, due to the widespread prevalence of thyroid disorders such as hypothyroidism, hyperthyroidism, and autoimmune thyroiditis.
The Canada is among the fastest-growing countries globally.
Abbott Laboratories, Beckman Coulter (Danaher), BioMérieux, Bio-Rad Laboratories, Bio-Techne Corporation, DiaSorin, EUROIMMUN AG, IDS (Immunodiagnostic Systems), Luminex Corporation, Nova Biomedical, Ortho Clinical Diagnostics, PerkinElmer, Promega Corporation, Quidel Corporation, Roche Diagnostics, Siemens Healthineers, Sigma-Aldrich (Merck Group), Thermo Fisher Scientific, Tosoh Bioscience, Trinity Biotech and Other Key Players
Table of Contents
- 1. Research Methodology and Assumptions
- 1.1. Definitions
- 1.2. Research Design and Approach
- 1.3. Data Collection Methods
- 1.4. Base Estimates and Calculations
- 1.5. Forecasting Models
- 1.5.1. Key Forecast Factors & Impact Analysis
- 1.6. Secondary Research
- 1.6.1. Open Sources
- 1.6.2. Paid Databases
- 1.6.3. Associations
- 1.7. Primary Research
- 1.7.1. Primary Sources
- 1.7.2. Primary Interviews with Stakeholders across Ecosystem
- 2. Executive Summary
- 2.1. Global Endocrine Testing Market Outlook
- 2.1.1. Endocrine Testing Market Size (Value - US$ Billion), and Forecasts, 2021-2035
- 2.1.2. Compounded Annual Growth Rate Analysis
- 2.1.3. Growth Opportunity Analysis
- 2.1.4. Segmental Share Analysis
- 2.1.5. Geographical Share Analysis
- 2.2. Market Analysis and Facts
- 2.3. Supply-Demand Analysis
- 2.4. Competitive Benchmarking
- 2.5. Go-to- Market Strategy
- 2.5.1. Customer/ End Use Industry Assessment
- 2.5.2. Growth Opportunity Data, 2025-2035
- 2.5.2.1. Regional Data
- 2.5.2.2. Country Data
- 2.5.2.3. Segmental Data
- 2.5.3. Identification of Potential Market Spaces
- 2.5.4. GAP Analysis
- 2.5.5. Potential Attractive Price Points
- 2.5.6. Prevailing Market Risks & Challenges
- 2.5.7. Preferred Sales & Marketing Strategies
- 2.5.8. Key Recommendations and Analysis
- 2.5.9. A Way Forward
- 2.1. Global Endocrine Testing Market Outlook
- 3. Industry Data and Premium Insights
- 3.1. Global Healthcare & Pharmaceutical Overview, 2025
- 3.1.1. Industry Ecosystem Analysis
- 3.1.2. Key Trends for Healthcare & Pharmaceutical Industry
- 3.1.3. Regional Distribution for Healthcare & Pharmaceutical
- 3.2. Supplier Customer Data
- 3.3. Technology Roadmap and Developments
- 3.1. Global Healthcare & Pharmaceutical Overview, 2025
- 4. Market Overview
- 4.1. Market Dynamics
- 4.1.1. Drivers
- 4.1.1.1. Rising prevalence of endocrine disorders including diabetes and thyroid dysfunction, especially amid aging and sedentary lifestyles.
- 4.1.1.2. Advancements in diagnostic technologies such as high‑sensitivity immunoassays and LC‑MS/MS enhancing accuracy and efficiency.
- 4.1.1.3. Growing awareness and emphasis on preventive healthcare boosting routine screening and point‑of‑care testing.
- 4.1.2. Restraints
- 4.1.2.1. High costs associated with advanced testing equipment, assays, and R&D hinder access, especially in developing regions
- 4.1.1. Drivers
- 4.2. Key Trend Analysis
- 4.3. Regulatory Framework
- 4.3.1. Key Regulations, Norms, and Subsidies, by Key Countries
- 4.3.2. Tariffs and Standards
- 4.3.3. Impact Analysis of Regulations on the Market
- 4.4. Value Chain Analysis/ Ecosystem Analysis
- 4.4.1. Raw Material/ Reagent Suppliers
- 4.4.2. Diagnostic Equipment & Assay Manufacturers
- 4.4.3. Distributors & Diagnostic Labs
- 4.4.4. End Users
- 4.5. Cost Structure Analysis
- 4.5.1. Parameter’s Share for Cost Associated
- 4.5.2. COGP vs COGS
- 4.5.3. Profit Margin Analysis
- 4.6. Porter’s Five Forces Analysis
- 4.7. PESTEL Analysis
- 4.8. Global Endocrine Testing Market Demand
- 4.8.1. Historical Market Size - in Value (Value - US$ Billion), 2021-2024
- 4.8.2. Current and Future Market Size - in Value (Value - US$ Billion), 2025–2035
- 4.8.2.1. Y-o-Y Growth Trends
- 4.8.2.2. Absolute $ Opportunity Assessment
- 4.1. Market Dynamics
- 5. Competition Landscape
- 5.1. Competition structure
- 5.1.1. Fragmented v/s consolidated
- 5.2. Company Share Analysis, 2025
- 5.2.1. Global Company Market Share
- 5.2.2. By Region
- 5.2.2.1. North America
- 5.2.2.2. Europe
- 5.2.2.3. Asia Pacific
- 5.2.2.4. Middle East
- 5.2.2.5. Africa
- 5.2.2.6. South America
- 5.3. Product Comparison Matrix
- 5.3.1. Specifications
- 5.3.2. Market Positioning
- 5.3.3. Pricing
- 5.1. Competition structure
- 6. Global Endocrine Testing Market Analysis, by Test Type
- 6.1. Key Segment Analysis
- 6.2. Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, by Test Type, 2021-2035
- 6.2.1. Thyroid Function Tests (T3, T4, TSH)
- 6.2.2. Adrenal Function Tests (Cortisol, ACTH)
- 6.2.3. Reproductive Hormone Tests (Estrogen, Progesterone, Testosterone, LH, FSH)
- 6.2.4. Glucose-related Tests (Insulin, C-peptide)
- 6.2.5. Calcium & Parathyroid Tests (PTH, Calcium levels)
- 6.2.6. Others
- 7. Global Endocrine Testing Market Analysis, by Mounting Type
- 7.1. Key Segment Analysis
- 7.2. Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, by Mounting Type, 2021-2035
- 7.2.1. Immunoassays (e.g., ELISA, CLIA)
- 7.2.2. Mass Spectrometry (e.g., LC-MS/MS)
- 7.2.3. Radioimmunoassays (RIA)
- 7.2.4. Chromatography-based Techniques
- 7.2.5. Point-of-Care Testing Devices
- 7.2.6. Others
- 8. Global Endocrine Testing Market Analysis, by Sample Type
- 8.1. Key Segment Analysis
- 8.2. Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, by Sample Type, 2021-2035
- 8.2.1. Serum/ Plasma
- 8.2.2. Urine
- 8.2.3. Saliva
- 8.2.4. Blood (Whole Blood Fingerstick)
- 8.2.5. Others
- 9. Global Endocrine Testing Market Analysis, by Mode of Testing
- 9.1. Key Segment Analysis
- 9.2. Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, by Mode of Testing, 2021-2035
- 9.2.1. Automated High-throughput Testing
- 9.2.2. Manual/ Manual Batch Testing
- 9.2.3. Semi-automated Testing
- 10. Global Endocrine Testing Market Analysis, by Pricing Tier
- 10.1. Key Segment Analysis
- 10.2. Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, by Pricing Tier, 2021-2035
- 10.2.1. Basic Panels
- 10.2.2. Advanced Multiplex Panels
- 10.2.3. Customized Hormone Profiling Packages
- 10.2.4. Others
- 11. Global Endocrine Testing Market Analysis, by Indication/ Application
- 11.1. Key Segment Analysis
- 11.2. Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, by Indication/ Application, 2021-2035
- 11.2.1. Diagnostic Screening (e.g., thyroid dysfunction)
- 11.2.2. Disease Monitoring (e.g., diabetes, adrenal disorders)
- 11.2.3. Fertility & Reproductive Health
- 11.2.4. Growth & Development Assessments
- 11.2.5. Clinical Research & Drug Development
- 11.2.6. Others
- 12. Global Endocrine Testing Market Analysis, by End-User Setting
- 12.1. Key Segment Analysis
- 12.2. Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, by End-User Setting, 2021-2035
- 12.2.1. Hospital Laboratories
- 12.2.2. Diagnostic and Reference Labs
- 12.2.3. Point-of-Care Clinics
- 12.2.4. Research Institutes
- 12.2.5. Home Testing Kits
- 12.2.6. Others
- 13. Global Endocrine Testing Market Analysis and Forecasts, by Region
- 13.1. Key Findings
- 13.2. Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, by Region, 2021-2035
- 13.2.1. North America
- 13.2.2. Europe
- 13.2.3. Asia Pacific
- 13.2.4. Middle East
- 13.2.5. Africa
- 13.2.6. South America
- 14. North America Endocrine Testing Market Analysis
- 14.1. Key Segment Analysis
- 14.2. Regional Snapshot
- 14.3. North America Endocrine Testing Market Size Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 14.3.1. Test Type
- 14.3.2. Mounting Type
- 14.3.3. Sample Type
- 14.3.4. Mode of Testing
- 14.3.5. Pricing Tier
- 14.3.6. Indication/ Application
- 14.3.7. End-User Setting
- 14.3.8. Country
- 14.3.8.1. USA
- 14.3.8.2. Canada
- 14.3.8.3. Mexico
- 14.4. USA Endocrine Testing Market
- 14.4.1. Country Segmental Analysis
- 14.4.2. Test Type
- 14.4.3. Mounting Type
- 14.4.4. Sample Type
- 14.4.5. Mode of Testing
- 14.4.6. Pricing Tier
- 14.4.7. Indication/ Application
- 14.4.8. End-User Setting
- 14.5. Canada Endocrine Testing Market
- 14.5.1. Country Segmental Analysis
- 14.5.2. Test Type
- 14.5.3. Mounting Type
- 14.5.4. Sample Type
- 14.5.5. Mode of Testing
- 14.5.6. Pricing Tier
- 14.5.7. Indication/ Application
- 14.5.8. End-User Setting
- 14.6. Mexico Endocrine Testing Market
- 14.6.1. Country Segmental Analysis
- 14.6.2. Test Type
- 14.6.3. Mounting Type
- 14.6.4. Sample Type
- 14.6.5. Mode of Testing
- 14.6.6. Pricing Tier
- 14.6.7. Indication/ Application
- 14.6.8. End-User Setting
- 15. Europe Endocrine Testing Market Analysis
- 15.1. Key Segment Analysis
- 15.2. Regional Snapshot
- 15.3. Europe Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 15.3.1. Test Type
- 15.3.2. Mounting Type
- 15.3.3. Sample Type
- 15.3.4. Mode of Testing
- 15.3.5. Pricing Tier
- 15.3.6. Indication/ Application
- 15.3.7. End-User Setting
- 15.3.8. Country
- 15.3.8.1. Germany
- 15.3.8.2. United Kingdom
- 15.3.8.3. France
- 15.3.8.4. Italy
- 15.3.8.5. Spain
- 15.3.8.6. Netherlands
- 15.3.8.7. Nordic Countries
- 15.3.8.8. Poland
- 15.3.8.9. Russia & CIS
- 15.3.8.10. Rest of Europe
- 15.4. Germany Endocrine Testing Market
- 15.4.1. Country Segmental Analysis
- 15.4.2. Test Type
- 15.4.3. Mounting Type
- 15.4.4. Sample Type
- 15.4.5. Mode of Testing
- 15.4.6. Pricing Tier
- 15.4.7. Indication/ Application
- 15.4.8. End-User Setting
- 15.5. United Kingdom Endocrine Testing Market
- 15.5.1. Country Segmental Analysis
- 15.5.2. Test Type
- 15.5.3. Mounting Type
- 15.5.4. Sample Type
- 15.5.5. Mode of Testing
- 15.5.6. Pricing Tier
- 15.5.7. Indication/ Application
- 15.5.8. End-User Setting
- 15.6. France Endocrine Testing Market
- 15.6.1. Country Segmental Analysis
- 15.6.2. Test Type
- 15.6.3. Mounting Type
- 15.6.4. Sample Type
- 15.6.5. Mode of Testing
- 15.6.6. Pricing Tier
- 15.6.7. Indication/ Application
- 15.6.8. End-User Setting
- 15.7. Italy Endocrine Testing Market
- 15.7.1. Country Segmental Analysis
- 15.7.2. Test Type
- 15.7.3. Mounting Type
- 15.7.4. Sample Type
- 15.7.5. Mode of Testing
- 15.7.6. Pricing Tier
- 15.7.7. Indication/ Application
- 15.7.8. End-User Setting
- 15.8. Spain Endocrine Testing Market
- 15.8.1. Country Segmental Analysis
- 15.8.2. Test Type
- 15.8.3. Mounting Type
- 15.8.4. Sample Type
- 15.8.5. Mode of Testing
- 15.8.6. Pricing Tier
- 15.8.7. Indication/ Application
- 15.8.8. End-User Setting
- 15.9. Netherlands Endocrine Testing Market
- 15.9.1. Country Segmental Analysis
- 15.9.2. Test Type
- 15.9.3. Mounting Type
- 15.9.4. Sample Type
- 15.9.5. Mode of Testing
- 15.9.6. Pricing Tier
- 15.9.7. Indication/ Application
- 15.9.8. End-User Setting
- 15.10. Nordic Countries Endocrine Testing Market
- 15.10.1. Country Segmental Analysis
- 15.10.2. Test Type
- 15.10.3. Mounting Type
- 15.10.4. Sample Type
- 15.10.5. Mode of Testing
- 15.10.6. Pricing Tier
- 15.10.7. Indication/ Application
- 15.10.8. End-User Setting
- 15.11. Poland Endocrine Testing Market
- 15.11.1. Country Segmental Analysis
- 15.11.2. Test Type
- 15.11.3. Mounting Type
- 15.11.4. Sample Type
- 15.11.5. Mode of Testing
- 15.11.6. Pricing Tier
- 15.11.7. Indication/ Application
- 15.11.8. End-User Setting
- 15.12. Russia & CIS Endocrine Testing Market
- 15.12.1. Country Segmental Analysis
- 15.12.2. Test Type
- 15.12.3. Mounting Type
- 15.12.4. Sample Type
- 15.12.5. Mode of Testing
- 15.12.6. Pricing Tier
- 15.12.7. Indication/ Application
- 15.12.8. End-User Setting
- 15.13. Rest of Europe Endocrine Testing Market
- 15.13.1. Country Segmental Analysis
- 15.13.2. Test Type
- 15.13.3. Mounting Type
- 15.13.4. Sample Type
- 15.13.5. Mode of Testing
- 15.13.6. Pricing Tier
- 15.13.7. Indication/ Application
- 15.13.8. End-User Setting
- 16. Asia Pacific Endocrine Testing Market Analysis
- 16.1. Key Segment Analysis
- 16.2. Regional Snapshot
- 16.3. East Asia Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 16.3.1. Test Type
- 16.3.2. Mounting Type
- 16.3.3. Sample Type
- 16.3.4. Mode of Testing
- 16.3.5. Pricing Tier
- 16.3.6. Indication/ Application
- 16.3.7. End-User Setting
- 16.3.8. Country
- 16.3.8.1. China
- 16.3.8.2. India
- 16.3.8.3. Japan
- 16.3.8.4. South Korea
- 16.3.8.5. Australia and New Zealand
- 16.3.8.6. Indonesia
- 16.3.8.7. Malaysia
- 16.3.8.8. Thailand
- 16.3.8.9. Vietnam
- 16.3.8.10. Rest of Asia Pacific
- 16.4. China Endocrine Testing Market
- 16.4.1. Country Segmental Analysis
- 16.4.2. Test Type
- 16.4.3. Mounting Type
- 16.4.4. Sample Type
- 16.4.5. Mode of Testing
- 16.4.6. Pricing Tier
- 16.4.7. Indication/ Application
- 16.4.8. End-User Setting
- 16.5. India Endocrine Testing Market
- 16.5.1. Country Segmental Analysis
- 16.5.2. Test Type
- 16.5.3. Mounting Type
- 16.5.4. Sample Type
- 16.5.5. Mode of Testing
- 16.5.6. Pricing Tier
- 16.5.7. Indication/ Application
- 16.5.8. End-User Setting
- 16.6. Japan Endocrine Testing Market
- 16.6.1. Country Segmental Analysis
- 16.6.2. Test Type
- 16.6.3. Mounting Type
- 16.6.4. Sample Type
- 16.6.5. Mode of Testing
- 16.6.6. Pricing Tier
- 16.6.7. Indication/ Application
- 16.6.8. End-User Setting
- 16.7. South Korea Endocrine Testing Market
- 16.7.1. Country Segmental Analysis
- 16.7.2. Test Type
- 16.7.3. Mounting Type
- 16.7.4. Sample Type
- 16.7.5. Mode of Testing
- 16.7.6. Pricing Tier
- 16.7.7. Indication/ Application
- 16.7.8. End-User Setting
- 16.8. Australia and New Zealand Endocrine Testing Market
- 16.8.1. Country Segmental Analysis
- 16.8.2. Test Type
- 16.8.3. Mounting Type
- 16.8.4. Sample Type
- 16.8.5. Mode of Testing
- 16.8.6. Pricing Tier
- 16.8.7. Indication/ Application
- 16.8.8. End-User Setting
- 16.9. Indonesia Endocrine Testing Market
- 16.9.1. Country Segmental Analysis
- 16.9.2. Test Type
- 16.9.3. Mounting Type
- 16.9.4. Sample Type
- 16.9.5. Mode of Testing
- 16.9.6. Pricing Tier
- 16.9.7. Indication/ Application
- 16.9.8. End-User Setting
- 16.10. Malaysia Endocrine Testing Market
- 16.10.1. Country Segmental Analysis
- 16.10.2. Test Type
- 16.10.3. Mounting Type
- 16.10.4. Sample Type
- 16.10.5. Mode of Testing
- 16.10.6. Pricing Tier
- 16.10.7. Indication/ Application
- 16.10.8. End-User Setting
- 16.11. Thailand Endocrine Testing Market
- 16.11.1. Country Segmental Analysis
- 16.11.2. Test Type
- 16.11.3. Mounting Type
- 16.11.4. Sample Type
- 16.11.5. Mode of Testing
- 16.11.6. Pricing Tier
- 16.11.7. Indication/ Application
- 16.11.8. End-User Setting
- 16.12. Vietnam Endocrine Testing Market
- 16.12.1. Country Segmental Analysis
- 16.12.2. Test Type
- 16.12.3. Mounting Type
- 16.12.4. Sample Type
- 16.12.5. Mode of Testing
- 16.12.6. Pricing Tier
- 16.12.7. Indication/ Application
- 16.12.8. End-User Setting
- 16.13. Rest of Asia Pacific Endocrine Testing Market
- 16.13.1. Country Segmental Analysis
- 16.13.2. Test Type
- 16.13.3. Mounting Type
- 16.13.4. Sample Type
- 16.13.5. Mode of Testing
- 16.13.6. Pricing Tier
- 16.13.7. Indication/ Application
- 16.13.8. End-User Setting
- 17. Middle East Endocrine Testing Market Analysis
- 17.1. Key Segment Analysis
- 17.2. Regional Snapshot
- 17.3. Middle East Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 17.3.1. Test Type
- 17.3.2. Mounting Type
- 17.3.3. Sample Type
- 17.3.4. Mode of Testing
- 17.3.5. Pricing Tier
- 17.3.6. Indication/ Application
- 17.3.7. End-User Setting
- 17.3.8. Country
- 17.3.8.1. Turkey
- 17.3.8.2. UAE
- 17.3.8.3. Saudi Arabia
- 17.3.8.4. Israel
- 17.3.8.5. Rest of Middle East
- 17.4. Turkey Endocrine Testing Market
- 17.4.1. Country Segmental Analysis
- 17.4.2. Test Type
- 17.4.3. Mounting Type
- 17.4.4. Sample Type
- 17.4.5. Mode of Testing
- 17.4.6. Pricing Tier
- 17.4.7. Indication/ Application
- 17.4.8. End-User Setting
- 17.5. UAE Endocrine Testing Market
- 17.5.1. Country Segmental Analysis
- 17.5.2. Test Type
- 17.5.3. Mounting Type
- 17.5.4. Sample Type
- 17.5.5. Mode of Testing
- 17.5.6. Pricing Tier
- 17.5.7. Indication/ Application
- 17.5.8. End-User Setting
- 17.6. Saudi Arabia Endocrine Testing Market
- 17.6.1. Country Segmental Analysis
- 17.6.2. Test Type
- 17.6.3. Mounting Type
- 17.6.4. Sample Type
- 17.6.5. Mode of Testing
- 17.6.6. Pricing Tier
- 17.6.7. Indication/ Application
- 17.6.8. End-User Setting
- 17.7. Israel Endocrine Testing Market
- 17.7.1. Country Segmental Analysis
- 17.7.2. Test Type
- 17.7.3. Mounting Type
- 17.7.4. Sample Type
- 17.7.5. Mode of Testing
- 17.7.6. Pricing Tier
- 17.7.7. Indication/ Application
- 17.7.8. End-User Setting
- 17.8. Rest of Middle East Endocrine Testing Market
- 17.8.1. Country Segmental Analysis
- 17.8.2. Test Type
- 17.8.3. Mounting Type
- 17.8.4. Sample Type
- 17.8.5. Mode of Testing
- 17.8.6. Pricing Tier
- 17.8.7. Indication/ Application
- 17.8.8. End-User Setting
- 18. Africa Endocrine Testing Market Analysis
- 18.1. Key Segment Analysis
- 18.2. Regional Snapshot
- 18.3. Africa Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 18.3.1. Test Type
- 18.3.2. Mounting Type
- 18.3.3. Sample Type
- 18.3.4. Mode of Testing
- 18.3.5. Pricing Tier
- 18.3.6. Indication/ Application
- 18.3.7. End-User Setting
- 18.3.8. Country
- 18.3.8.1. South Africa
- 18.3.8.2. Egypt
- 18.3.8.3. Nigeria
- 18.3.8.4. Algeria
- 18.3.8.5. Rest of Africa
- 18.4. South Africa Endocrine Testing Market
- 18.4.1. Country Segmental Analysis
- 18.4.2. Test Type
- 18.4.3. Mounting Type
- 18.4.4. Sample Type
- 18.4.5. Mode of Testing
- 18.4.6. Pricing Tier
- 18.4.7. Indication/ Application
- 18.4.8. End-User Setting
- 18.5. Egypt Endocrine Testing Market
- 18.5.1. Country Segmental Analysis
- 18.5.2. Test Type
- 18.5.3. Mounting Type
- 18.5.4. Sample Type
- 18.5.5. Mode of Testing
- 18.5.6. Pricing Tier
- 18.5.7. Indication/ Application
- 18.5.8. End-User Setting
- 18.6. Nigeria Endocrine Testing Market
- 18.6.1. Country Segmental Analysis
- 18.6.2. Test Type
- 18.6.3. Mounting Type
- 18.6.4. Sample Type
- 18.6.5. Mode of Testing
- 18.6.6. Pricing Tier
- 18.6.7. Indication/ Application
- 18.6.8. End-User Setting
- 18.7. Algeria Endocrine Testing Market
- 18.7.1. Country Segmental Analysis
- 18.7.2. Test Type
- 18.7.3. Mounting Type
- 18.7.4. Sample Type
- 18.7.5. Mode of Testing
- 18.7.6. Pricing Tier
- 18.7.7. Indication/ Application
- 18.7.8. End-User Setting
- 18.8. Rest of Africa Endocrine Testing Market
- 18.8.1. Country Segmental Analysis
- 18.8.2. Test Type
- 18.8.3. Mounting Type
- 18.8.4. Sample Type
- 18.8.5. Mode of Testing
- 18.8.6. Pricing Tier
- 18.8.7. Indication/ Application
- 18.8.8. End-User Setting
- 19. South America Endocrine Testing Market Analysis
- 19.1. Key Segment Analysis
- 19.2. Regional Snapshot
- 19.3. Central and South Africa Endocrine Testing Market Size (Value - US$ Billion), Analysis, and Forecasts, 2021-2035
- 19.3.1. Test Type
- 19.3.2. Mounting Type
- 19.3.3. Sample Type
- 19.3.4. Mode of Testing
- 19.3.5. Pricing Tier
- 19.3.6. Indication/ Application
- 19.3.7. End-User Setting
- 19.3.8. Country
- 19.3.8.1. Brazil
- 19.3.8.2. Argentina
- 19.3.8.3. Rest of South America
- 19.4. Brazil Endocrine Testing Market
- 19.4.1. Country Segmental Analysis
- 19.4.2. Test Type
- 19.4.3. Mounting Type
- 19.4.4. Sample Type
- 19.4.5. Mode of Testing
- 19.4.6. Pricing Tier
- 19.4.7. Indication/ Application
- 19.4.8. End-User Setting
- 19.5. Argentina Endocrine Testing Market
- 19.5.1. Country Segmental Analysis
- 19.5.2. Test Type
- 19.5.3. Mounting Type
- 19.5.4. Sample Type
- 19.5.5. Mode of Testing
- 19.5.6. Pricing Tier
- 19.5.7. Indication/ Application
- 19.5.8. End-User Setting
- 19.6. Rest of South America Endocrine Testing Market
- 19.6.1. Country Segmental Analysis
- 19.6.2. Test Type
- 19.6.3. Mounting Type
- 19.6.4. Sample Type
- 19.6.5. Mode of Testing
- 19.6.6. Pricing Tier
- 19.6.7. Indication/ Application
- 19.6.8. End-User Setting
- 20. Key Players/ Company Profile
- 20.1. Abbott Laboratories
- 20.1.1. Company Details/ Overview
- 20.1.2. Company Financials
- 20.1.3. Key Customers and Competitors
- 20.1.4. Business/ Industry Portfolio
- 20.1.5. Product Portfolio/ Specification Details
- 20.1.6. Pricing Data
- 20.1.7. Strategic Overview
- 20.1.8. Recent Developments
- 20.2. Beckman Coulter (Danaher)
- 20.3. BioMerieux
- 20.4. Bio-Rad Laboratories
- 20.5. Bio-Techne Corporation
- 20.6. DiaSorin
- 20.7. EUROIMMUN AG
- 20.8. IDS (Immunodiagnostic Systems)
- 20.9. Luminex Corporation
- 20.10. Nova Biomedical
- 20.11. Ortho Clinical Diagnostics
- 20.12. PerkinElmer
- 20.13. Promega Corporation
- 20.14. Quidel Corporation
- 20.15. Roche Diagnostics
- 20.16. Siemens Healthineers
- 20.17. Sigma-Aldrich (Merck Group)
- 20.18. Thermo Fisher Scientific
- 20.19. Tosoh Bioscience
- 20.20. Trinity Biotech
- 20.21. Other Key Players
- 20.1. Abbott Laboratories
Note* - This is just tentative list of players. While providing the report, we will cover a greater number of players based on their revenue and share for each geography
Our research design integrates both demand-side and supply-side analysis through a balanced combination of primary and secondary research methodologies. By utilizing both bottom-up and top-down approaches alongside rigorous data triangulation methods, we deliver robust market intelligence that supports strategic decision-making.
MarketGenics' comprehensive research design framework ensures the delivery of accurate, reliable, and actionable market intelligence. Through the integration of multiple research approaches, rigorous validation processes, and expert analysis, we provide our clients with the insights needed to make informed strategic decisions and capitalize on market opportunities.
MarketGenics leverages a dedicated industry panel of experts and a comprehensive suite of paid databases to effectively collect, consolidate, and analyze market intelligence.
Our approach has consistently proven to be reliable and effective in generating accurate market insights, identifying key industry trends, and uncovering emerging business opportunities.
Through both primary and secondary research, we capture and analyze critical company-level data such as manufacturing footprints, including technical centers, R&D facilities, sales offices, and headquarters.
Our expert panel further enhances our ability to estimate market size for specific brands based on validated field-level intelligence.
Our data mining techniques incorporate both parametric and non-parametric methods, allowing for structured data collection, sorting, processing, and cleaning.
Demand projections are derived from large-scale data sets analyzed through proprietary algorithms, culminating in robust and reliable market sizing.
The bottom-up approach builds market estimates by starting with the smallest addressable market units and systematically aggregating them to create comprehensive market size projections.
This method begins with specific, granular data points and builds upward to create the complete market landscape.
Customer Analysis → Segmental Analysis → Geographical Analysis
The top-down approach starts with the broadest possible market data and systematically narrows it down through a series of filters and assumptions to arrive at specific market segments or opportunities.
This method begins with the big picture and works downward to increasingly specific market slices.
TAM → SAM → SOM
While analysing the market, we extensively study secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and commercial report. Secondary sources that we utilize are not only the public sources, but it is combination of Open Source, Associations, Paid Databases, MG Repository & Knowledgebase and Others.
- Company websites, annual reports, financial reports, broker reports, and investor presentations
- National government documents, statistical databases and reports
- News articles, press releases and web-casts specific to the companies operating in the market, Magazines, reports, and others
- We gather information from commercial data sources for deriving company specific data such as segmental revenue, share for geography, product revenue, and others
- Internal and external proprietary databases (industry-specific), relevant patent, and regulatory databases
- Governing Bodies, Government Organizations
- Relevant Authorities, Country-specific Associations for Industries
We also employ the model mapping approach to estimate the product level market data through the players product portfolio
Primary research/ interviews is vital in analyzing the market. Most of the cases involves paid primary interviews. Primary sources includes primary interviews through e-mail interactions, telephonic interviews, surveys as well as face-to-face interviews with the different stakeholders across the value chain including several industry experts.
| Type of Respondents | Number of Primaries |
|---|---|
| Tier 2/3 Suppliers | ~20 |
| Tier 1 Suppliers | ~25 |
| End-users | ~25 |
| Industry Expert/ Panel/ Consultant | ~30 |
| Total | ~100 |
MG Knowledgebase
• Repository of industry blog, newsletter and case studies
• Online platform covering detailed market reports, and company profiles
- Historical Trends – Past market patterns, cycles, and major events that shaped how markets behave over time. Understanding past trends helps predict future behavior.
- Industry Factors – Specific characteristics of the industry like structure, regulations, and innovation cycles that affect market dynamics.
- Macroeconomic Factors – Economic conditions like GDP growth, inflation, and employment rates that affect how much money people have to spend.
- Demographic Factors – Population characteristics like age, income, and location that determine who can buy your product.
- Technology Factors – How quickly people adopt new technology and how much technology infrastructure exists.
- Regulatory Factors – Government rules, laws, and policies that can help or restrict market growth.
- Competitive Factors – Analyzing competition structure such as degree of competition and bargaining power of buyers and suppliers.
Multiple Regression Analysis
- Identify and quantify factors that drive market changes
- Statistical modeling to establish relationships between market drivers and outcomes
Time Series Analysis – Seasonal Patterns
- Understand regular cyclical patterns in market demand
- Advanced statistical techniques to separate trend, seasonal, and irregular components
Time Series Analysis – Trend Analysis
- Identify underlying market growth patterns and momentum
- Statistical analysis of historical data to project future trends
Expert Opinion – Expert Interviews
- Gather deep industry insights and contextual understanding
- In-depth interviews with key industry stakeholders
Multi-Scenario Development
- Prepare for uncertainty by modeling different possible futures
- Creating optimistic, pessimistic, and most likely scenarios
Time Series Analysis – Moving Averages
- Sophisticated forecasting for complex time series data
- Auto-regressive integrated moving average models with seasonal components
Econometric Models
- Apply economic theory to market forecasting
- Sophisticated economic models that account for market interactions
Expert Opinion – Delphi Method
- Harness collective wisdom of industry experts
- Structured, multi-round expert consultation process
Monte Carlo Simulation
- Quantify uncertainty and probability distributions
- Thousands of simulations with varying input parameters
Our research framework is built upon the fundamental principle of validating market intelligence from both demand and supply perspectives. This dual-sided approach ensures comprehensive market understanding and reduces the risk of single-source bias.
Demand-Side Analysis: We understand end-user/application behavior, preferences, and market needs along with the penetration of the product for specific application.
Supply-Side Analysis: We estimate overall market revenue, analyze the segmental share along with industry capacity, competitive landscape, and market structure.
Data triangulation is a validation technique that uses multiple methods, sources, or perspectives to examine the same research question, thereby increasing the credibility and reliability of research findings. In market research, triangulation serves as a quality assurance mechanism that helps identify and minimize bias, validate assumptions, and ensure accuracy in market estimates.
- Data Source Triangulation – Using multiple data sources to examine the same phenomenon
- Methodological Triangulation – Using multiple research methods to study the same research question
- Investigator Triangulation – Using multiple researchers or analysts to examine the same data
- Theoretical Triangulation – Using multiple theoretical perspectives to interpret the same data
